Thanks Monti - it's all there, Pharma has been knocking on the door since the P2 results were announced.
We just need to read between the lines.
- Delay in EMA PIP process...on purpose by ANP imo.
- Pivot to get FDA guidance asap!
- Push to get "Fast Track designation" with FDA
- Alignment of endpoints and trial design between EMA and FDA
- The FDA approval of higher doses for Phase 2B
- Lack of detail about the monkey tox studies logistics / funding.
- Dr Voit as PI for Phase 2B - is patent owner of Sarapta's GT 'micro-dystrophin' IP
- Lack of 'senior appointments' so far, sans Dr Gittleson...mentioned at AGM
- Delay of 'new in indications' news
"The Company would advise the market should these interactions lead to a material transaction."
The ducks are aligned with both EMA and FDA agreeing to same endpoints, dose regiment, ambulant and non-ambulant population...throw in maybe a combination therapy?
Now it's about the $$$...and Morgans in their research note are estimating a $350m licensing deal.
That partnership deal needs to be larger given the opportunity.
BUT then, if you were Sarepta...you might as well try a $2.50 cash and script offer.
Sarepta has the most to lose if ANP succeeds.
.
- Forums
- ASX - By Stock
- PER
- Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-128
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M |
Open | High | Low | Value | Volume |
7.7¢ | 8.0¢ | 7.7¢ | $134.7K | 1.732M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 99278 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 122500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 99278 | 0.077 |
1 | 10000 | 0.075 |
1 | 104866 | 0.074 |
1 | 12990 | 0.073 |
2 | 400000 | 0.072 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 122500 | 1 |
0.080 | 222798 | 2 |
0.081 | 120000 | 1 |
0.083 | 206000 | 2 |
0.085 | 250000 | 2 |
Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
Last
7.7¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
7.9¢ | 8.0¢ | 7.7¢ | 70281 | ||
Last updated 15.51pm 07/05/2024 ? |
Featured News
PER (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online